What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
George Somlo focuses on Internal medicine, Oncology, Breast cancer, Surgery and MEDLINE.
His work in Multiple myeloma, Chemotherapy, Combination therapy and Bone marrow are all subfields of Internal medicine research.
His Oncology study combines topics from a wide range of disciplines, such as Clinical trial, Disease, Trastuzumab and General surgery.
His Breast cancer study combines topics in areas such as Radiation therapy and Adjuvant therapy.
The various areas that he examines in his Surgery study include Gastroenterology and Thalidomide.
The Cancer study combines topics in areas such as Cancer research and Adverse effect.
His most cited work include:
- Association of reactive oxygen species levels and radioresistance in cancer stem cells (1700 citations)
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline (1410 citations)
- Clinical practice guidelines in oncology (1369 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Oncology, Breast cancer, Chemotherapy and Surgery.
His Internal medicine study typically links adjacent topics like Gastroenterology.
The concepts of his Oncology study are interwoven with issues in Carboplatin, Trastuzumab, Adjuvant therapy and Pathology.
His Breast cancer research is multidisciplinary, relying on both Cancer research, Clinical trial and Radiation therapy.
George Somlo has included themes like Regimen, Toxicity and Pharmacology in his Chemotherapy study.
Many of his studies involve connections with topics such as Thalidomide and Surgery.
He most often published in these fields:
- Internal medicine (69.14%)
- Oncology (44.29%)
- Breast cancer (36.29%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (69.14%)
- Oncology (44.29%)
- Breast cancer (36.29%)
In recent papers he was focusing on the following fields of study:
George Somlo mostly deals with Internal medicine, Oncology, Breast cancer, Cancer research and Cancer.
Internal medicine is closely attributed to Gastroenterology in his work.
George Somlo has researched Oncology in several fields, including Chemotherapy, Lenalidomide, Carboplatin, Adjuvant chemotherapy and Metastatic breast cancer.
His Breast cancer research incorporates elements of Biopsy and Immune system.
His studies deal with areas such as Carcinogenesis, Palbociclib, STAT3, Triple-negative breast cancer and Estrogen as well as Cancer research.
His Cancer study incorporates themes from Neurosurgery, Mesenchymal stem cell and Neurooncology.
Between 2016 and 2021, his most popular works were:
- Clinical practice guidelines in oncology (1369 citations)
- NCCN Guidelines® insights breast cancer, version 1.2017: Featured updates to the NCCN Guidelines (221 citations)
- JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. (200 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Internal medicine, Oncology, Breast cancer, Cancer research and Cancer.
His work often combines Internal medicine and PARP inhibitor studies.
He combines subjects such as Nausea, Carboplatin, Chemotherapy and Pharmacology with his study of Oncology.
His work carried out in the field of Breast cancer brings together such families of science as Disease management, Disease and Retrospective cohort study.
His studies in Cancer research integrate themes in fields like Carcinogenesis, PI3K/AKT/mTOR pathway, Estrogen receptor, STAT3 and Triple-negative breast cancer.
His research in the fields of Cancer stem cell, Metastasis and Metastatic breast cancer overlaps with other disciplines such as Leptin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
